- Home
- NMI vs ANIX Comparison
NMI vs ANIX Comparison
Compare NMI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMI
- ANIX
- Stock Information
- Founded
- NMI 1988
- ANIX 1982
- Country
- NMI United States
- ANIX United States
- Employees
- NMI N/A
- ANIX N/A
- Industry
- NMI Trusts Except Educational Religious and Charitable
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- NMI Finance
- ANIX Health Care
- Exchange
- NMI Nasdaq
- ANIX Nasdaq
- Market Cap
- NMI 97.2M
- ANIX 101.4M
- IPO Year
- NMI N/A
- ANIX 1987
- Fundamental
- Price
- NMI $9.57
- ANIX $3.08
- Analyst Decision
- NMI
- ANIX Strong Buy
- Analyst Count
- NMI 0
- ANIX 2
- Target Price
- NMI N/A
- ANIX $8.50
- AVG Volume (30 Days)
- NMI 28.4K
- ANIX 128.3K
- Earning Date
- NMI 01-01-0001
- ANIX 01-14-2025
- Dividend Yield
- NMI 4.10%
- ANIX N/A
- EPS Growth
- NMI N/A
- ANIX N/A
- EPS
- NMI N/A
- ANIX N/A
- Revenue
- NMI N/A
- ANIX N/A
- Revenue This Year
- NMI N/A
- ANIX N/A
- Revenue Next Year
- NMI N/A
- ANIX N/A
- P/E Ratio
- NMI N/A
- ANIX N/A
- Revenue Growth
- NMI N/A
- ANIX N/A
- 52 Week Low
- NMI $8.30
- ANIX $2.15
- 52 Week High
- NMI $10.05
- ANIX $5.13
- Technical
- Relative Strength Index (RSI)
- NMI 31.10
- ANIX 42.34
- Support Level
- NMI $9.58
- ANIX $3.07
- Resistance Level
- NMI $9.68
- ANIX $4.20
- Average True Range (ATR)
- NMI 0.08
- ANIX 0.30
- MACD
- NMI 0.01
- ANIX -0.06
- Stochastic Oscillator
- NMI 40.70
- ANIX 2.61
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.